Biohaven cut R&D by about 60% and pivoted toward obesity after the FDA rejected its spinocerebellar ataxia therapy.
Longevity News
After an FDA rejection of its spinocerebellar ataxia therapy, Biohaven was forced to rethink its strategy—cutting R&D...
Source: FierceBiotech - All • Published: 20 Feb 2026, 21:00
Continue exploring
Related longevity signals
Nature - MainA binding-to-release strategy for targeted anticancer drug delivery - NatureCovers a chemistry-driven binding-to-release strategy that enables targeted payload release from cell-surface receptors without cellular internalization, expanding conjugate targets.Frontiers - HealthAcute otitis media complicated by mastoiditis and otogenic transverse-sigmoid sinus thrombosis in an adult: a case report on infectious pathogenesis and multidisciplinary therapyA clinical case describing adult acute otitis media that progressed to mastoiditis with sigmoid plate erosion and transverse-sigmoid sinus thrombosis, and multidisciplinary management.Longevity TechnologyXellSmart scores FDA fast track for Parkinson’s cell therapyNews about regulatory momentum for an off-the-shelf cell therapy for Parkinson’s, previewing a piece on its clinical and manufacturing implications.Longevity TechnologyAlzeCure’s $12m payday fuels new brain-aging therapyA business-focused article explaining a biotech licensing and investment deal that hands a brain-aging drug platform to a better-funded developer, and why that matters for future development.